Efficacy and safety of anlotinib in 16 patients with advanced non-small cell lung cancer
10.3760/cma.j.issn.0578-1426.2018.11.007
- VernacularTitle:安罗替尼治疗晚期非小细胞肺癌16例临床分析
- Author:
Xiaoyan SI
1
;
Hanping WANG
;
Xiaotong ZHANG
;
Mengzhao WANG
;
Li ZHANG
Author Information
1. 100730,中国医学科学院北京协和医学院北京协和医院呼吸内科
- Keywords:
Anlotinib;
Carcinoma;
non-small cell lung;
Targeted therapy
- From:
Chinese Journal of Internal Medicine
2018;57(11):830-834
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer (NSCLC).Methods Patients with stageⅢB/ⅣNSCLC who progressed after two lines or more regimens were randomized into anlotinib group (12 mg daily from day 1 to 14 of a 21-day cycle) or placebo group with ratio of 2:1. Study drugs or placebo were given until disease progression or intolerable toxicity. The primary endpoint was overall survival (OS), and the second endpoints were progression free survival (PFS), objective response rate, and disease control rate. Results Between April 2015 and December 2015, twenty-four patients were assigned at Peking Union Medical College Hospital. The baseline characteristics of the anlotinib group (n=16) and placebo group (n=8) were fairly comparable. The median OS was 12.7 months in anlotinib group and 11.1 months in placebo group (P=0.460). The median PFS was 4.0 months in anlotinib group and 1.4 months in placebo group (P=0.065). The common adverse events were manageable such as hypertension, hand-foot syndrome, thyroiddy sfunction. No drug-related mortality occurred. Conclusions Anlotinib had a trend of improvement in OS and PFS as third-line treatment or beyond in advanced NSCLC compared with placebo with manageable toxicity.
